Most recent guideline publication:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016)
Updates since publication:
No updates on dosing recommendations since publication.
Tables provided in the main manuscript of the guideline:
|Table 1. Assignment of likely CYP2D6 phenotypes based on diplotypes|
|Table 2. Dosing recommendations for ondansetron and tropisetron based on CYP2D6 genotype|
Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016)
Tables and figures provided in the guideline publication supplement or referenced in the guidelinea:
|Supplemental Table S1. Association between allelic variants and CYP2D6 enzyme activity|
|Supplemental Table S2. Evidence linking CYP2D6 to ondansetron and tropisetron phenotype|
|Supplemental Table S3. Cytochrome P450 enzymes involved in the metabolism of 5-HT3 receptor antagonist|
|CYP2D6 allele definition table|
|CYP2D6 allele functionality table|
|CYP2D6 frequency table|
|CYP2D6 diplotype-phenotype table|
Gene Resource Mapping
Drug Resource Mapping
Clinical Decision Support:b
aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.